货号:A1378139 同义名: CompK;compound K
HPK1-IN-7是一种高效的口服活性HPK1抑制剂,能够选择性地抑制HPK1,具有广泛的抗肿瘤潜力,尤其是在结合免疫检查点抑制剂时。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | HPK1-IN-7 is a potent and orally active inhibitor of HPK1 (hematopoietic progenitor kinase 1, MAP4K1), exhibiting an IC50 of 2.6 nM, along with remarkable family and kinome selectivity. It demonstrates selectivity against IRAK4 (59 nM) and GLK (140 nM), and exhibits robust efficacy in the MC38 syngeneic tumor model when combined with anti-PD1 [1]. |
体内研究 | HPK1-IN-7 (100 mg/kg; orally; twice daily for 28 days) significantly enhances the efficacy of anti-PD1 treatment in a colorectal cancer syngeneic tumor model [1]. HPK1-IN-7 (1 mg/kg; intravenous; in mice) displays moderate plasma clearance (43 mL/min/kg) and a large volume of distribution (4.4 L/kg). After oral administration (20 mg/kg), it achieves a Cmax of 5.3 μM and an AUC0-24h of 19 μM•h. Based on these pharmacokinetic findings, the calculated oral bioavailability is approximately 100% [1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.18mL 0.44mL 0.22mL |
10.91mL 2.18mL 1.09mL |
21.81mL 4.36mL 2.18mL |
CAS号 | 2320462-65-3 |
分子式 | C24H22N6O4 |
分子量 | 458.469 |
别名 | CompK;compound K;HPK1-IN 7, HPK1-IN7 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Sealed in dry,Room Temperature |
溶解度 |
DMSO: 120 mg/mL(261.74 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |